Watch PRLD. Know when insiders buy.
One email the day a filing lands. Free.
PRLD
Prelude Therapeutics Inc
3.45
−0.07 −1.99%
USD · close Nov 13
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
66
PASS · shorts 66
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $275.3MP/E —DIV YIELD —FCF YIELD -12.08%REV TTM $22.4M +220.3%NET INCOME −$60.5MNET CASH —52W 1.35 – 6.63SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $5.7M | — | — | −$15.5M | −$13.9M | — | -0.14 | −$15.6M | $0 | −$15.6M | Aug 11 |
| Q1 2026 · Mar 31 | $4.6M | — | — | −$14.2M | −$10.4M | — | -0.13 | −$21.7M | $0 | −$21.7M | Aug 11 |
| Q4 2025 · Dec 31derived | $5.6M | +41.0% | — | −$17.3M | −$16.5M | — | -0.20 | $23.1M | $0 | $23.1M | Mar 10 |
| Q3 2025 · Sep 30 | $6.5M | +116.7% | — | −$20.4M | −$19.7M | — | -0.26 | −$19.1M | $0 | −$19.1M | Nov 12 |
| Q2 2025 · Jun 30 | $0 | — | — | −$32.2M | −$31.2M | — | -0.41 | −$26.1M | $20K | −$26.1M | Aug 11 |
| Q1 2025 · Mar 31 | $0 | — | — | −$34.6M | −$32.1M | — | -0.42 | −$34.2M | $47K | −$34.3M | Aug 11 |
| Q4 2024 · Dec 31derived | $4M | — | — | −$33.8M | −$28.7M | — | -0.38 | −$20.7M | $53K | −$20.8M | Mar 10 |
| Q3 2024 · Sep 30 | $3M | — | — | −$34.4M | −$32.3M | — | -0.43 | −$27.3M | $63K | −$27.4M | Nov 12 |
| Q2 2024 · Jun 30 | — | — | — | −$37.2M | −$34.7M | — | -0.46 | −$23.1M | $359K | −$23.4M | Nov 12 |
| Q1 2024 · Mar 31 | — | — | — | −$34.3M | −$31.4M | — | -0.42 | −$31.8M | $289K | −$32.1M | Nov 12 |
| Q4 2023 · Dec 31derived | — | — | — | −$37.4M | −$33.1M | — | -0.47 | −$23.6M | $1.1M | −$24.7M | Mar 10 |
| Q3 2023 · Sep 30 | — | — | — | −$33.4M | −$30.6M | — | -0.45 | −$25.7M | $591K | −$26.3M | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $12.1M | — | −$104.6M | −$99.5M | -819.6% | -1.29 | −$56.3M | $67K | −$56.4M | — | — |
| FY2024 · to Dec 31 | $7M | — | −$139.7M | −$127.2M | -1816.8% | -1.68 | −$102.9M | $764K | −$103.7M | — | — |
| FY2023 · to Dec 31 | — | — | −$132.3M | −$121.8M | — | -2.02 | −$107.1M | $3.5M | −$110.6M | — | — |
| FY2022 · to Dec 31 | — | — | −$123.5M | −$115.4M | — | -2.44 | −$83.7M | $3M | −$86.7M | — | — |
| FY2021 · to Dec 31 | — | — | −$113.7M | −$111.7M | — | -2.43 | −$83.5M | $2.3M | −$85.9M | — | — |
| FY2020 · to Dec 31 | — | — | −$58.8M | −$56.9M | — | -4.56 | −$46.2M | $621K | −$46.8M | — | — |
Every number comes from Prelude Therapeutics Inc's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.